| UNIVERSITY OF KANSAS Patent applications |
| Patent application number | Title | Published |
|---|
| 20130123149 | Polyelectrolyte Complexes for Oil and Gas Applications - A polyelectrolyte complex for the controlled release of an oil and gas field chemical selected from the group consisting of (a) a gel-forming or cross-linking agent, (b) a scale inhibitor, (c) a corrosion inhibitor, (d) an inhibitor of asphaltene or wax deposition, (e) a hydrogen sulfide scavenger, (f) a hydrate inhibitor, (g) a breaking agent, and a surfactant. | 05-16-2013 |
| 20130099196 | Semiconductor-Graphene Hybrids Formed Using Solution Growth - A novel method for fabrication of hybrid semiconductor-graphene nanostructures in large scale by floating graphene sheets on the surface of a solution is provided. Using this approach, crystalline ZnO nano/micro-rod bundles on graphene fabricated using chemical vapor deposition were prepared. UV detectors fabricated using the as-prepared hybrid ZnO-graphene nano-structure with graphene being one of the two electrodes show high sensitivity to ultraviolet light, suggesting the graphene remained intact during the ZnO growth. This growth process provides a low-cost and robust scheme for large-scale fabrication of semiconductor nanostructures on graphene and may be applied for synthesis of a variety of hybrid semiconductor-graphene nano-structures demanded for optoelectronic applications including photovoltaics, photodetection, and photocatalysis. | 04-25-2013 |
| 20130096070 | PEPTIDE TARGETING OF INNER EAR CELLS - Peptide targeting moieties that target the cells of the inner ear can be used for targeted therapeutics. As such, nucleic acids and/or drugs can be associated with the targeting moieties in order to provide therapeutics that are delivered to specific cells in the inner ear. Conjugation of drugs or gene therapy vectors to cell specific peptides may allow the treatment of individual cell types within the inner ear. The peptide targeting moieties can be polypeptides having the sequences of Table 1 in an unnatural configuration. The polynucleotide can either consist of the sequence or include additional polypeptides attached to the ends of the sequences shown in Table 1. The polynucleotide can be in a non-native configuration. For example, the polypeptide is selected from the following: a-h-p-h-h-s-m (SEQ ID NO: 12); h-p-h-h-r-i-f (SEQ ID NO: 29); t-v-p-q-l-t-t (SEQ ID NO: 1); s-t-t-k-l-a-l (SEQ ID NO: 2); m-e-g-y-i-h-r (SEQ ID NO: 3); h-a-i-y-p-r-h (SEQ ID NO: 5); h-s-r-l-l-d-q (SEQ ID NO: 6); i-q-s-p-h-f-f (SEQ ID NO: 7); or y-a-a-h-r-s-h (SEQ ID NO: 8). | 04-18-2013 |
| 20130023796 | METHOD AND APPARATUS FOR MEASURING NON-NUTRITIVE SUCK PATTERN STABILITY - Method and apparatus are provided for generating an index associated with non-nutritive suck pattern stability. An example apparatus can include an STI generator configured to generate a plurality of non-nutritive suck (NNS) pressure samples using a non-nutritive pacifier and a pressure transducer, and to sum a plurality of standard deviations based on the plurality of NNS pressure samples to provide a spatiotemporal index (STI) of non-nutritive suck pattern stability, wherein the STI is configured to provide a composite indication of variability of amplitude, and duration of a plurality of portions of the NNS pressure samples. | 01-24-2013 |
| 20130018172 | Metal Abstraction Peptide and Uses Thereof - Compositions comprising certain tripeptides which are capable of binding a metal in a square planar orientation, a square pyramidal orientation, or both, are disclosed in processes for modulating tagged peptides or proteins. Such compositions and processes may be used for site-specific chiral inversion of amino acids, site-specific peptide cleavage, and protein purification, among other uses. | 01-17-2013 |
| 20120329987 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 12-27-2012 |
| 20120328678 | Hydrogel Networks Having Living Cells Encapsulated Therein - The present invention is directed to a hydrogel network comprised of a physically cross-linked polymer and a chemically cross-linked polymer or physically entangled copolymer containing living cells, such as chondrocytes, encapsulated therein. In a preferred aspect, the physically cross-linked polymer is selected from the group consisting of thermally gelling polysaccharides and proteins, such as agarose or gelatin, and the chemically cross-linked or physically entangled polymer is synthesized from a water-soluble vinyl monomer, either as a homopolymer or copolymer, such as polyethylene glycol diacrylate (“PEG-DA”) and 2-hydroxyethyl methacrylate (“HEMA”). | 12-27-2012 |
| 20120309702 | DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 - An inhibitor of heat shock protein 90 (HSP90) can include a coumermycin A1 analog having a structure that inhibits HSP90 greater than coumermycin A1. That is, the coumermycin A1 analog is not coumermycin A1. The coumermycin A1 analog can have an antiproliferative biological activity, which can be superior to coumermycin A1. The activity can include the coumermycin A1 analog inhibiting a C-terminus of HSP90. | 12-06-2012 |
| 20120270313 | Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State - The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor. | 10-25-2012 |
| 20120269510 | DIGITAL SUBCARRIER OPTICAL NETWORK UTILIZING DIGITAL SUBCARRIER CROSS-CONNECTS WITH INCREASED ENERGY EFFICIENCY - The present invention provides reduced power dissipation and other benefits at the optical transport network layer by utilizing a digital subcarrier optical network comprising multiple digital subcarrier cross-connect switches. This offers several advantages for optical networks, including spectral efficiency and robustness against signal corruption and consumption of less energy than traditional TDM-based electric switches (OTN/SONET/SDH). | 10-25-2012 |
| 20120259005 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 10-11-2012 |
| 20120237107 | SYSTEM AND METHODS FOR DIGITAL EVALUATION OF CELLBLOCK PREPARATIONS - Digital evaluation of cellblock preparations to determine the type and extent of disease in order to identify the best approach for treatment without the need for additional testing or sampling. | 09-20-2012 |
| 20120232118 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME - Potent and selective ligands for the dopamine 3 (D | 09-13-2012 |
| 20120208771 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS - Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine. | 08-16-2012 |
| 20120184590 | FORMULATIONS OF INDOLE-3-CARBINOL DERIVED ANTITUMOR AGENTS WITH INCREASED ORAL BIOAVAILABILITY - A pharmaceutical composition for treating, inhibiting, or preventing cancer can include an indole-3-carbinol derivative compound in a pharmaceutically acceptable carrier that is configured for oral administration. The indole-3-carbinol derivative compound can have antitumor activity, and oral administration can provide blood bioavailability of about 0.5% to about 25%. The pharmaceutically acceptable carrier can include a hydroxyl-fatty acid PEG monoester and/or diester. The carrier can be a hydroxyl-fatty acid PEG ester that includes 12-hydroxy stearate. The carrier can be a hydroxyl-fatty acid PEG ester that includes a PEG having from about 100 MW to about 200,000 MW. The indole-3-carbinol derivative can be 2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo-(2,3-b)carbazole. | 07-19-2012 |
| 20120177667 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
| 20120177580 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
| 20120177579 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
| 20120174712 | Metal Abstraction Peptide (MAP) Tag and Associated Methods - Compositions comprising a tripeptide having the sequence XC | 07-12-2012 |
| 20120037364 | DELAYED GELLING AGENTS - The invention is directed to delayed gelation agents comprising a degradable polymeric cage containing therein one or more gelation agents. The cage degrades in situ, e.g, in an oil reservoir, thus releasing the gelation agent(s), which can then crosslink second polymers in situ to form a gel. | 02-16-2012 |
| 20110190212 | CYCLIC TETRAPEPTIDES - Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and/or preventing stress-induced drug seeking behavior. | 08-04-2011 |
| 20110132398 | METHOD AND APPARATUS FOR ANTI-FOULING AN ANEMOMETER - An apparatus and method for adaptive materials arranged in a variety of orientations and with a wide range of attachment configurations to induce structural vibrations at extremely high frequencies. These mechanical vibrations cause fouling agents to become detached and accordingly “clean” an otherwise dirty element or wire of a hot-wire anemometer, planar or curvilinear sensor surface, or display surfaces. They also can be made to vibrate at such frequencies with such intensities that local droplets of water are either shaken off or instantaneously cavitate, thereby allowing the elements to be used in all weather conditions. | 06-09-2011 |
| 20110082098 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE - Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof. | 04-07-2011 |
| 20110038727 | METHOD AND APPARATUS FOR PRESSURE ADAPTIVE MORPHING STRUCTURE - A method and apparatus for a novel adaptive aerostructure is presented that relies on certified aerospace materials and can therefore be applied in conventional passenger aircraft. This structure consists of a honeycomb material which cells extend over a significant length perpendicular to the plane of the cells. Each of the cells contains an inelastic pouch (or bladder) that forms a circular tube when the cell forms a perfect hexagon. By changing the cell differential pressure (CDP) the stiffness of the honeycomb can be altered. Using an external force or the elastic force within the honeycomb material, the honeycomb can be deformed such that the cells deviate from their perfect-hexagonal shape. It can be shown that by increasing the CDP, the structure eventually returns to a perfect hexagon. By doing so, a fully embedded pneumatic actuator is created that can perform work and substitute conventional low-bandwidth flight control actuators. It is shown that two approaches can be taken to regulate the stiffness of this embedded actuator. | 02-17-2011 |
| 20100314115 | SWELLABLE POLYMER WITH CATIONIC SITES - The invention is directed to long lasting crosslinked water-soluble swellable polymers, methods for making same, and their uses. More particularly, the invention relates to a composition comprising expandable polymeric particles having cationic sites as well as labile crosslinkers and stable crosslinkers, said particle mixed with a fluid. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric particles are injected into a target zones in the reservoirs and when the heat and/or a suitable pH in the reservoir cause degradation of the labile crosslinker and when the particle expands, the cationic sites in the polymer adsorb to negative sites of the rock in the formation, thus diverting water to lower permeability regions and improving oil recovery. However, many other uses are possible. | 12-16-2010 |
| 20100314114 | SWELLABLE POLYMER WITH ANIONIC SITES - The invention is directed to stable crosslinked water-soluble swellable polymers and methods for making same. More particularly, the invention relates to a composition comprising expandable polymeric particles having anionic sites and labile crosslinkers and stable crosslinkers, said particle mixed with a fluid and a cationic crosslinker that is capable of further crosslinking the particle on degradation of the labile crosslinker and exposure of the anionic sites so as to form a gel. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric particles are injected into target zone and when the heat and/or suitable pH of the target zone cause degradation of the labile crosslinker and the particle expands, the cationic crosslinker crosslinks the polymer to form a gel, thus diverting water to lower permeability regions and improving oil recovery. | 12-16-2010 |
| 20100292109 | SWELLABLE POLYMERS WITH HYDROPHOBIC GROUPS - The invention is directed to crosslinked water-soluble swellable polymers, methods for making same and their various uses. More particularly, the invention relates to a composition comprising expandable polymeric particles being made with 0.1-5% hydrophobic monomers and labile crosslinkers and stable crosslinkers, said particles mixed with a fluid. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric particles are injected into a well and when the heat and/or pH of the target zones in the formation cause degradation of the labile crosslinker and when the particle expands, the hydrophobic groups associate to form a hydrophobically associative polymer, thus diverting water to lower permeability regions and improving oil recovery. | 11-18-2010 |
| 20100232887 | BREAKAWAY CASING CONNECTION - A temporary casing is disclosed. The casing includes a primary portion capable of being driven into the ground and comprising a hollow portion wherein soil may be removed from within the primary casing portion, a detachable portion, also being capable of being driven into the ground and comprising a hollow portion wherein soil may be removed from within the detachable portion, a connection means for connecting the primary casing to the detachable portion such that the connection means enables the transfer of the driving force applied to the primary casing portion to the detachable portion in order to drive the detachable portion into the ground in association with the primary casing portion, wherein the connection means causes the detachable portion to detach from the primary portion when a threshold force is applied to the connection means and allows retrieval of at least the primary portion. | 09-16-2010 |
| 20100108807 | TETHERED HOVERING PLATFORM - The design and refinement of a tethered hovering platform into a feasible working system is presented. To determine a starting point for the design, a detailed historical search was conducted to find the history and the current state of such technology. Real world current needs are analyzed to produce a mission specification and to drive the preliminary vehicle design. Analysis of environmental conditions and decisions about an initial payload package are made in conjunction with motor and propeller sizing. Initial concept testing to discover feasibility and operational issues was performed; from this, instability issues were discovered. Analyzing these instability issues using known rotorcraft and momentum effects, in conjunction with flight testing, yields possible solutions to the problem. The use of constrained layer dampers as a means of passive stabilization is addressed and suggested as the preferred solution. Testing of passive constrained layer damping verifies the stability of the solution. The system components and manufacturing cost is presented in comparison to current systems using active stabilization | 05-06-2010 |
| 20100105630 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS - Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders. | 04-29-2010 |
| 20100099865 | HEAT SHOCK PROTEIN 90 INHIBITORS - Novel compounds useful for inhibiting the 90kDa heat shock proteins containing a quinone-like moiety and a di-hydroxy phenol like moiety, similar to geldanamycin and radicicol. | 04-22-2010 |
| 20100048882 | Novobiocin Analogues as Anticancer Agents - Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents. | 02-25-2010 |
| 20100022635 | Heat shock protein 90 inhibitor dosing methods - The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days. | 01-28-2010 |
| 20090182220 | SOURCE AFFINE RECONSTRUCTION FOR MEDICAL IMAGING - Performing medical imaging. The generation of medical images, which includes a Source AFFine Image REconstruction (SAFFIRE) algorithm, is based on an iterative implementation of minimum mean-square error (MMSE) estimation within an affine-transformed solution space and utilizes a matched filter bank initialization coupled with energy normalization of each successive estimate. An incoherent integration technique provides an alternative implementation strategy to either increase signal-to-noise ratio (SNR) or generalize the estimator to accommodate temporally-separated interference sources. In addition, the estimator solution may be employed to determine volumetric constraints with which to re-apply the estimator to further improve the estimation accuracy. | 07-16-2009 |
| 20090170842 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 07-02-2009 |
| 20090098209 | PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION - The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states. | 04-16-2009 |
| 20080286245 | PREPARATION OF REGULATORY T CELLS USING ICAM-1 CO-STIMULATION - A method for generating a purified regulatory T cell composition having a CD4 | 11-20-2008 |
| 20080248102 | Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan - The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent. | 10-09-2008 |
| 20080223578 | Polyelectrolyte Complexes as Delayed Gelling Agents for Oil and Gas Applications - A polyelectrolyte complex for the controlled or delayed gelation of a water and hydrocarbon producing subterranean formation. | 09-18-2008 |
